DSIP in Sleep and Neuropeptide Research

DSIP was named in 1977 for the deep sleep it seemed to trigger in rabbits. Nearly fifty years later, nobody has found its gene or its receptor.

Delta sleep-inducing peptide, or DSIP, is a nine-amino-acid peptide first characterized by Schoenenberger and Monnier in 1977 (PNAS, 1977). They isolated it from the cerebral venous blood of rabbits during sleep induced by electrically stimulating the thalamus, and named it for the delta waves of deep sleep. The name sounds more settled than the science. A 2006 review in the Journal of Neurochemistry called DSIP “a still unresolved riddle” (Kovalzon and Strekalova, 2006). This post covers where it came from, what the human studies found, and why the questions never closed.

Table of Contents

• Where DSIP Came From
• The Questions That Never Closed
• The 1980s Human Studies
• DSIP Research Today
• FDA Status
• FAQs About DSIP

Where DSIP Came From

The 1970s were a busy decade for sleep chemistry. Researchers were hunting for a circulating “sleep factor,” a substance that builds up in the body and pushes the brain toward sleep.

Schoenenberger and Monnier’s approach was direct. They put rabbits to sleep by stimulating the thalamus, collected blood draining from the brain, and looked for something in it that could induce the slow delta waves of deep sleep in other animals. The peptide they characterized became DSIP (1977). A year later, the same group reported its amino-acid sequence and a synthetic version of the nine-residue peptide (1978).

A synthetic version meant other labs could study it, and they did, for about the next decade.

The Questions That Never Closed

Most signaling peptides can be traced back to a gene that encodes them and a receptor they act on. DSIP has neither. No gene, precursor protein, or dedicated receptor for DSIP has been identified (Kovalzon and Strekalova, 2006).

That gap feeds a bigger doubt. Without a known source or target, researchers have questioned whether DSIP is a genuine sleep-regulating factor at all, or a peptide that turned up in the right place at the right time.

Stability is another complication. A 1987 study documented DSIP and two of its analogs degrading and aggregating in blood plasma and serum (Graf et al., 1987). A peptide that breaks down or clumps quickly in blood is hard to study, because it’s unclear how much intact peptide reaches its target in any given experiment.

The 1980s Human Studies

DSIP did reach human testing. Most of that work came from D. Schneider-Helmert and colleagues, who studied synthetic DSIP in people with disturbed sleep and chronic insomnia:

• An early report on synthetic DSIP and disturbed human sleep (1981)
• A study titled simply “DSIP in insomnia” (1984)
• A study of 24-hour sleep-wake behavior in severe chronic insomnia (1987)

A separate group tested short-term DSIP in chronic insomnia patients the same year (Monti et al., 1987).

These studies were small, and the results were mixed. None settled whether DSIP reliably changes human sleep. The research then largely went quiet. We found no controlled insomnia trials of DSIP on PubMed after the 1980s.

DSIP Research Today

Today DSIP shows up mostly in reviews, as an open question rather than an active line of trials. The unknowns are the same ones researchers flagged decades ago:

• Whether DSIP is made by the body through a dedicated pathway, since no gene or precursor has been found
• What it binds to, since no specific receptor has been identified
• How much intact peptide survives in circulation, given its instability in plasma
• Whether the mixed 1980s findings would hold up in a larger, modern controlled trial

For a researcher, that makes DSIP an interesting historical puzzle and a weak foundation for assumptions. Our overview of what peptide safety research shows explains why small, decades-old studies can’t answer safety questions. If you’re new to the category, start with what peptides are and how they work.

FDA Status

DSIP is not an FDA-approved drug.

FDA’s page on bulk substances that may present significant safety risks lists emideltide (DSIP) in Category 2. That category covers substances nominated for use in drug compounding that FDA has flagged for possible significant safety risks. It applies to compounding pharmacies, a separate channel from research material. Emideltide was also on the agenda for FDA’s July 2026 Pharmacy Compounding Advisory Committee meeting, so its listing may change.

Research-grade DSIP is sold for laboratory work only. For that use, the certificate of analysis carries the weight: compound identity, HPLC purity, and a batch number that matches your vial. Our guide to evaluating research peptide quality walks through each check.

FAQs About DSIP

What does “delta sleep” mean?

Delta waves are the slow, high-amplitude brain waves recorded on an EEG during the deepest stage of non-REM sleep. DSIP was named for its apparent ability to promote that pattern in the original rabbit experiments.

Is DSIP a proven sleep aid?

No. The human studies from the 1980s were small and produced mixed results, and no modern controlled trials have followed. Researchers still debate whether DSIP is a true sleep factor.

Does the body make DSIP naturally?

That’s one of the open questions. It was isolated from rabbit blood, but no gene or precursor protein that would produce it has been identified.

Is DSIP the same as emideltide?

Yes. Emideltide is the name FDA uses for DSIP on its compounding lists, where it appears in Category 2.

How should DSIP be stored?

Lyophilized powder keeps best cold and away from light, and DSIP’s known instability in plasma is a reminder that handling matters. Check the product documentation and certificate of analysis for your vial, and see our lab handling guide.

All products are sold strictly for lawful laboratory research purposes only and are not for human or veterinary use or human consumption. This article summarizes published research for general information and is not a substitute for advice from your doctor. References: each study named above links to its record on PubMed, ClinicalTrials.gov, or FDA.gov.